Research programme: pain and inflammation therapeutics - Angelini
Latest Information Update: 28 Oct 2019
Price :
$50 *
At a glance
- Originator Angelini Group
- Class Pyridines; Small molecules
- Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Pain
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for research development in Inflammation in Italy
- 28 Oct 2019 No recent reports of development identified for research development in Pain in Italy
- 14 Sep 2015 Early research in Inflammation in Italy (unspecified route)